Literature DB >> 21288802

Influenza neuraminidase-inhibiting antibodies are induced in the presence of zanamivir.

Ishrat Sultana1, Jin Gao, Lewis Markoff, Maryna C Eichelberger.   

Abstract

Seasonal influenza epidemics cause illness and death each year, and the emergence of antigenically novel influenza A viruses are a continual pandemic threat. Disease and death can be averted by vaccination. The potency of killed virus vaccines is based on hemagglutinin (HA) content. However, antibodies that inhibit enzyme activity of the neuraminidase (NA) also reduce virus replication and protect against disease. Monoclonal NA-inhibiting (NI) antibodies recognize conformational epitopes, and it is anticipated that native tertiary structure is required for their induction. NA assembles as a tetramer and only this form has enzyme activity. Since small inhibitors of NA do not significantly alter conformation, we sought to determine whether neuraminidase-inhibiting (NI) antibodies would be induced by inhibitor-inactivated NA. We therefore evaluated responses of mice immunized with purified NA that was either inactivated by addition of zanamivir or denatured by heat treatment. NI antibodies were induced following immunization with NA from A/Wisconsin/67/2005 (H3N2) in which enzyme activity was inhibited by the former method but not the latter. Protection of mice against challenge with virus containing an antigenically matched NA correlated with the detection of NI antibodies in serum. Similar results were obtained when mice were immunized with whole H1N1 virus in which NA activity had been inhibited by the same two modalities. This demonstrates that native conformation of NA is necessary for induction of NI antibodies; enzyme activity provides a useful marker of intact structure, but absence of activity in NA that is correctly folded does not result in loss of immunogenicity. Thus any assay to assess potency of influenza vaccines with respect to NA content should consider the proportion of NA that is in a structurally native state.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21288802     DOI: 10.1016/j.vaccine.2011.01.047

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  10 in total

1.  Neuraminidase, the Forgotten Surface Antigen, Emerges as an Influenza Vaccine Target for Broadened Protection.

Authors:  Maryna C Eichelberger; Arnold S Monto
Journal:  J Infect Dis       Date:  2019-04-08       Impact factor: 5.226

2.  Generation of a reassortant avian influenza virus H5N2 vaccine strain capable of protecting chickens against infection with Egyptian H5N1 and H9N2 viruses.

Authors:  Ahmed Kandeil; Yassmin Moatasim; Mokhtar R Gomaa; Mahmoud M Shehata; Rabeh El-Shesheny; Ahmed Barakat; Richard J Webby; Mohamed A Ali; Ghazi Kayali
Journal:  Vaccine       Date:  2015-11-25       Impact factor: 3.641

Review 3.  Neuraminidase as an influenza vaccine antigen: a low hanging fruit, ready for picking to improve vaccine effectiveness.

Authors:  Maryna C Eichelberger; David M Morens; Jeffery K Taubenberger
Journal:  Curr Opin Immunol       Date:  2018-04-16       Impact factor: 7.486

Review 4.  Recent Progress in Recombinant Influenza Vaccine Development Toward Heterosubtypic Immune Response.

Authors:  Mark B Carascal; Rance Derrick N Pavon; Windell L Rivera
Journal:  Front Immunol       Date:  2022-05-19       Impact factor: 8.786

5.  Broadened immunity against influenza by vaccination with computationally designed influenza virus N1 neuraminidase constructs.

Authors:  E R Job; T Ysenbaert; A Smet; I Christopoulou; T Strugnell; E O Oloo; R P Oomen; H Kleanthous; T U Vogel; X Saelens
Journal:  NPJ Vaccines       Date:  2018-11-29       Impact factor: 7.344

6.  The effect of calcium and magnesium on activity, immunogenicity, and efficacy of a recombinant N1/N2 neuraminidase vaccine.

Authors:  Luca T Giurgea; Jae-Keun Park; Kathie-Anne Walters; Kelsey Scherler; Adriana Cervantes-Medina; Ashley Freeman; Luz Angela Rosas; John C Kash; Jeffery K Taubenberger; Matthew J Memoli
Journal:  NPJ Vaccines       Date:  2021-04-06       Impact factor: 7.344

Review 7.  Influenza Neuraminidase Characteristics and Potential as a Vaccine Target.

Authors:  Sarah Creytens; Mirte N Pascha; Marlies Ballegeer; Xavier Saelens; Cornelis A M de Haan
Journal:  Front Immunol       Date:  2021-11-16       Impact factor: 7.561

8.  Structure-based design of stabilized recombinant influenza neuraminidase tetramers.

Authors:  Daniel Ellis; Julia Lederhofer; Oliver J Acton; Yaroslav Tsybovsky; Sally Kephart; Christina Yap; Rebecca A Gillespie; Adrian Creanga; Audrey Olshefsky; Tyler Stephens; Deleah Pettie; Michael Murphy; Claire Sydeman; Maggie Ahlrichs; Sidney Chan; Andrew J Borst; Young-Jun Park; Kelly K Lee; Barney S Graham; David Veesler; Neil P King; Masaru Kanekiyo
Journal:  Nat Commun       Date:  2022-04-05       Impact factor: 17.694

9.  Potency under pressure: the impact of hydrostatic pressure on antigenic properties of influenza virus hemagglutinin.

Authors:  Schafer L Eichelberger; Ishrat Sultana; Jin Gao; Melkamu Getie-Kebtie; Michail Alterman; Maryna C Eichelberger
Journal:  Influenza Other Respir Viruses       Date:  2013-03-17       Impact factor: 4.380

10.  Protective efficacy of anti-neuraminidase monoclonal antibodies against H7N9 influenza virus infection.

Authors:  Fei-Fei Xiong; Xue-Ying Liu; Fei-Xia Gao; Jian Luo; Peng Duan; Wen-Song Tan; Ze Chen
Journal:  Emerg Microbes Infect       Date:  2020-01-02       Impact factor: 7.163

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.